Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $16 | $14 | $4 |
| % Growth | -74.6% | 11.7% | 219% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $16 | $14 | $4 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $70 | $73 | $85 | $104 |
| G&A Expenses | $23 | $31 | $26 | $29 |
| SG&A Expenses | $23 | $31 | $26 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $93 | $104 | $111 | $133 |
| Operating Income | -$89 | -$88 | -$98 | -$128 |
| % Margin | -2,259.9% | -567.5% | -701.7% | -2,943.8% |
| Other Income/Exp. Net | -$42 | $1 | $2 | $0 |
| Pre-Tax Income | -$131 | -$87 | -$96 | -$128 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$131 | -$88 | -$96 | -$128 |
| % Margin | -3,326% | -564.6% | -690.6% | -2,944.1% |
| EPS | -20.94 | -3.52 | -2.25 | -3.22 |
| % Growth | -494.9% | -56.4% | 30.1% | – |
| EPS Diluted | -20.94 | -3.52 | -2.25 | -3.22 |
| Weighted Avg Shares Out | 6 | 25 | 43 | 40 |
| Weighted Avg Shares Out Dil | 6 | 25 | 43 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $4 | $4 |
| EBITDA | -$87 | -$85 | -$94 | -$125 |
| % Margin | -2,193.5% | -547.7% | -675.2% | -2,857.1% |